Illumina next-generation sequencing (NGS) and microarray technologies represent the gold standard in quality worldwide—and account for ~90% of the world’s sequencing data.* Innovative, intuitive, and completely integrated, our sample-to-data solutions empower your lab to keep ahead of the curve in the rapidly evolving genomics revolution. So you’ll be better able to perform the world-class research you strive for—with the goal of uncovering new insights into the biology of cancer that can lead to meaningful advances in personalized medicine.
Our comprehensive product offerings support multiple cancer research applications, including studies of DNA, RNA, epigenetics, and more. Our range of sequencers can be scaled to meet your needs—from powerful, yet personal, benchtop models to versatile, high-throughput systems. With intuitive data analysis and management capabilities and unsurpassed customer support, we can deliver the answers you seek—quickly, accurately, and cost-effectively.
Explore genomics-based approaches to investigating cancer using NGS and microarrays.
NGS technology has accelerated the discovery of variants associated with cancer. Some of these research discoveries became the basis for companion diagnostics and laboratory developed tests (LDT) now in use in molecular diagnostic laboratories worldwide. We spoke with key opinion leaders about the ongoing challenges and potential of NGS in oncology testing.Read Interview
By: Dr. Phil Febbo, SVP and Chief Medical OfficerRead Article
Researchers are using next-generation sequencing to predict cancer risk and tailor precision prevention.Read Interview
By: Dr. Phil Febbo, Chief Medical Officer at IlluminaRead Article
*Data on file based on a 2013 study.